Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.
Roxana Mehran, Sunil V Rao, Deepak L Bhatt...
https://pubmed.ncbi.nlm.nih.gov/21670242/Actively Recruiting
Led by Leiden University Medical Center · Updated on 2025-02-19
111
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are evaluating treatments for patients with high-risk pulmonary embolism PE, a serious condition that requires immediate clot removal in addition to blood thinners. This trial compares two approaches catheter-directed thrombectomy CDT, a procedure that directly removes clots using a device, versus standard full-dose systemic thrombolysis, which dissolves clots using medication. The study aims to see if CDT can reduce death rates and serious complications better than the usual treatment, while also improving recovery and quality of life over one year. Participants are randomly assigned to one of two groups. One group receives the CDT procedure, where a catheter is guided through veins to the lungs to extract clots using suction, combined with blood thinners during the procedure. The other group receives full-dose systemic thrombolysis using clot-dissolving drugs such as Alteplase, Urokinase, or Tenecteplase. The study is open-label, meaning both patients and doctors know which treatment is given. Researchers will monitor effects at various points, including day 7, day 30, and up to one year after treatment. During the trial, participants undergo evaluations including clinical and hemodynamic assessments to determine treatment success, monitoring of oxygen levels, length of stay in intensive care and hospital, and quality of life questionnaires over a year. The main measure is a combined rate of death, treatment failure, major bleeding, and stroke at 30 days. Secondary outcomes include survival, bleeding events, oxygen use, and long-term functional recovery. Cost-effectiveness of the treatments will also be analyzed after one year.
CONDITIONS
'Thrombectomy in High-Risk Pulmonary Embolism - Device Versus Thrombolysis Netherlands': TORPEDO-NL
W
W. J.E. Stenger, MD
F
F. A. Klok, Prof. MD. PhD.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Leiden University Medical Center
Lead Sponsor
Dutch Heart Foundation
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Immediate intervention with follow-up up to 30 days
Participants receive either catheter-directed thrombectomy or systemic thrombolysis as treatment for high-risk pulmonary embolism.
1 treatment visit followed by multiple assessments up to 30 days
Duration - Up to 1 year
Participants are monitored for treatment outcomes, safety, and recovery including survival, bleeding events, and quality of life.
Visits at day 7, day 30, and additional assessments at 3, 6, 9, and 12 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Roxana Mehran, Sunil V Rao, Deepak L Bhatt...
https://pubmed.ncbi.nlm.nih.gov/21670242/Sonali Arora, Saraschandra Vallabhajosyula, Vikas Aggarwal...
https://pubmed.ncbi.nlm.nih.gov/38964819/Matthew Koslow, Gali Epstein Shochet, Feda Fenadka...
https://pubmed.ncbi.nlm.nih.gov/32466857/Christopher Kabrhel, Ikenna Okechukwu, Praveen Hariharan...
https://pubmed.ncbi.nlm.nih.gov/24846902/Roberta Pancani, Liliana Villari, Ferruccio Aquilini...
https://pubmed.ncbi.nlm.nih.gov/35849919/Menno V Huisman, Stefano Barco, Suzanne C Cannegieter...
https://pubmed.ncbi.nlm.nih.gov/29770793/Adam M Gwozdz, Cindy M M de Jong, Luz Sousa Fialho...
https://pubmed.ncbi.nlm.nih.gov/36055334/Scott R Evans, Daniel Rubin, Dean Follmann...
https://pubmed.ncbi.nlm.nih.gov/26113652/W J E Stenger, C A den Uil, W J R Rietdijk...
https://pubmed.ncbi.nlm.nih.gov/41027123/Yvonne M Ende-Verhaar, Lilian J Meijboom, Lucia J M Kroft...
https://pubmed.ncbi.nlm.nih.gov/30962147/Leiden University Medical Center
Lead Sponsor
Dutch Heart Foundation
Collaborating Sponsor